Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Non-Comparative, Two-Arm Open Label, Multiple-Center Study Of CP-751,871 In Combination With Docetaxel/Prednisone In Chemotherapy- Naive (Arm A) And Docetaxel/Prednisone Refractory (Arm B) Patients With Hormone Insensitive Prostate Cancer
To test the efficacy of CP-751,871 combined with docetaxel and prednisone in the treatment of prostate cancer that is refractory to hormone therapy
Age
18 - No limit years
Sex
MALE
Healthy Volunteers
No
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Orange, Ohio, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Berlin, Germany
Pfizer Investigational Site
München, Germany
Start Date
May 1, 2006
Primary Completion Date
April 1, 2011
Completion Date
December 1, 2011
Last Updated
April 11, 2013
204
ACTUAL participants
CP-751,871
DRUG
docetaxel
DRUG
prednisone
DRUG
docetaxel
DRUG
prednisone
DRUG
Lead Sponsor
Pfizer
NCT07225946
NCT04868604
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT00756665